Siamab develops drugs targeting cancers expressing abnormal carbohydrates (glycans) including ovarian, pancreatic, prostate, and other solid tumors.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free